- Home
- IPEX vs INO Comparison
IPEX vs INO Comparison
Compare IPEX & INO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$10.45
HOLD
Current Price
$1.41
Company Overview
Basic Information| Metric | IPEX | INO |
|---|---|---|
| Founded | 2024 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 123.4M | 114.0M |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | IPEX | INO |
|---|---|---|
| Price | $10.45 | $1.41 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.75 |
| AVG Volume (30 Days) | 17.2K | ★ 2.2M |
| Earning Date | 04-15-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.18 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $42,220,086.00 |
| Revenue This Year | N/A | $20,156.19 |
| Revenue Next Year | N/A | $421.95 |
| P/E Ratio | $41.16 | ★ N/A |
| Revenue Growth | N/A | ★ 19.37 |
| 52 Week Low | $10.25 | $1.03 |
| 52 Week High | $10.46 | $2.86 |
Technical Indicators
Market Signals| Indicator | IPEX | INO |
|---|---|---|
| Relative Strength Index (RSI) | 72.25 | 65.06 |
| Support Level | N/A | $1.35 |
| Resistance Level | $10.46 | $1.52 |
| Average True Range (ATR) | 0.01 | 0.07 |
| MACD | -0.00 | 0.05 |
| Stochastic Oscillator | 83.33 | 95.77 |
Price Performance
Historical Comparison IPEX
INO
About IPEX Inflection Point Acquisition Corp. V Class A Ordinary Shares
Inflection Point Acquisition Corp V is a blank check company.
About INO Inovio Pharmaceuticals Inc.
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.